SCHEMBL24469835

SCHEMBL24469835

CNC(=O)c1ccc(-n2c(=O)c3c(n4ncc(Cc5ccccc5)c24)CNCC3)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 4/20 0.39
HDAC1 Q13547 2/20 0.37
HDAC6 Q9UBN7 2/20 0.37
HSP90AA1 P07900 1/20 0.35
HSP90AB1 P08238 1/20 0.35
HTR2C P28335 1/20 0.35
MAPK11 Q15759 1/20 0.34
MAPK14 Q16539 1/20 0.34
BRD4 O60885 3/20 0.34
BRD2 P25440 1/20 0.34
BRD3 Q15059 1/20 0.34
BRDT Q58F21 1/20 0.34
VCP P55072 1/20 0.33
LMNA P02545 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
TSHR P16473 1/20 0.33
CASP1 P29466 1/20 0.33
CYP3A4 P08684 1/20 0.32
MCHR1 Q99705 1/20 0.32
USP7 Q93009 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22717418 0.90 EGLN1 (0.37) HDAC1HDAC6HSP90AA1HSP90AB1USP7
SCHEMBL24470064 0.88 HSP90AA1 (0.34) CRBNHDAC1HDAC6HSP90AA1HSP90AB1
SCHEMBL22845219 0.88 HTR2C (0.39) HTR2CTSHRCASP1CYP3A4MCHR1
SCHEMBL22845314 0.87 GCGR (0.41) HTR2C
Trifluoroacetic Acid SCHEMBL22717821 0.87 CTNNB1 (0.34) HDAC1HDAC6HSP90AA1HSP90AB1USP7
SCHEMBL24469782 0.86 HSP90AA1 (0.35) CRBNHDAC1HDAC6HSP90AA1HSP90AB1
SCHEMBL24469920 0.86 HSP90AA1 (0.35) CRBNHDAC1HDAC6HSP90AA1HSP90AB1
SCHEMBL24469867 0.85 CRBN (0.36) CRBNMAPK11MAPK14BRD4BRD2
SCHEMBL22845210 0.85 ALDH1A1 (0.42) HTR2CLMNASMN1; SMN2TSHRCASP1
SCHEMBL24470063 0.84 MTOR (0.35) CRBNHDAC1HDAC6HSP90AA1HSP90AB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11820773-B2 Tricyclic compounds ALIGOS THERAPEUTICS, INC. (US) 2023-11-21 US disclosed
US-11820773-B2 Tricyclic compounds ALIGOS THERAPEUTICS, INC. (US) 2023-11-21 US disclosed
WO-2022115384-A1 TRICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. (US) 2022-06-02 WO disclosed
US-20220169650-A1 TRICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. 2022-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220169650-A1 TRICYCLIC COMPOUNDS SLC10A1, PKD1, CEL CRBN 4086/4885HDAC1 47/4885HDAC6 12/4885
US-11820773-B2 Tricyclic compounds SLC10A1, PKD1, CEL CRBN 4086/4885HDAC1 47/4885HDAC6 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.